Merck & Co.'s Stock Soars Amid Patent Pressures

Merck & Co., Inc. (MRK) is one of the world's leading pharmaceutical giants, known for developing breakthrough medicines and vaccines that have transformed healthcare globally.

The company has a strong presence across oncology, vaccines, infectious diseases, and animal health, with blockbuster products like Keytruda driving its growth.

Merck's stock has surged 58.8% over the past year and gained 22% year-to-date (YTD) in 2026, comfortably outperforming the S&P 500 Index ($SPX), which has returned 22.6% over the past year and 13% in 2026.

The pharmaceutical giant's resilience is attributed to Keytruda, the world's best-selling cancer drug, despite growing competitive pressures and looming patent exclusivity in 2028.